2025-12-06 - Analysis Report
Okay, here's a breakdown of Natera Inc. (NTRA) based on the data provided, aiming for clarity and simplicity:

**0. Report Introduction**

This report analyzes Natera Inc. (NTRA), a company focused on genetic testing, comparing its performance against the S&P 500 (VOO) and examining recent market data, news, and financial information.

**1. Return Rate Comparison**

*   **NTRA Company Overview:** Natera Inc. is a genetic testing company focusing on reproductive health, oncology, and organ health.
*   **NTRA Cumulative Return:** 144.07%
*   **VOO Cumulative Return:** 101.54%
*   **Divergence:**
    *   Current: 43.6
    *   Relative Divergence: 50.2 (This indicates the current divergence is at the median of its historical range).

**Analysis:** NTRA has significantly outperformed the S&P 500. The divergence is positive, showing NTRA's superior return. However, the relative divergence of 50.2 suggests the divergence is currently in the middle range compared to its historical fluctuations.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD   | Alpha   | Beta  | Cap(B) |
|------------|---------|-------|---------|-------|--------|
| 2015-2017  | -10.0%  | 70.1% | -34.0%  | -0.2  | 1.3    |
| 2016-2018  | 22.0%   | 80.0% | 6.0%    | 0.1   | 2.0    |
| 2017-2019  | 50.0%   | 80.0% | 28.0%   | 1.0   | 4.7    |
| 2018-2020  | 186.0%  | 80.5% | 163.0%  | 1.1   | 14.0   |
| 2019-2021  | 96.0%   | 80.5% | 49.0%   | 1.6   | 13.1   |
| 2020-2022  | -77.0%  | 80.5% | -76.0%  | 0.1   | 5.7    |
| 2021-2023  | -194.0% | 76.6% | -195.0% | -1.1  | 8.8    |
| 2022-2024  | 8.0%    | 76.6% | -13.0%  | -1.2  | 22.3   |
| 2023-2025  | 171.0%  | 76.6% | 105.0%  | 0.1   | 33.5   |

**Analysis:**

*   **CAGR:** Demonstrates high volatility, with periods of significant growth and decline.
*   **MDD:**  Maximum Drawdown remains consistently high, indicating significant risk.
*   **Alpha:**  Shows periods of outperformance (positive Alpha) and underperformance (negative Alpha) relative to the market.
*   **Beta:**  Fluctuates, indicating changing sensitivity to market movements. Beta values exceeding 1 indicate the stock is more volatile than the market.
*   **Cap(B):** Market capitalization is generally increasing over time, reflecting the company's growth.

**2. Recent Stock Price Fluctuations**

*   **Current Close:** 238.21
*   **Last Market Data:** Price: 242.67, Previous Close: 242.06, Change: 0.25
*   **5-day SMA:** 237.66
*   **20-day SMA:** 219.17
*   **60-day SMA:** 191.40

**Analysis:** The stock price is currently above all three moving averages, suggesting an upward trend. The 5-day SMA being above the 20-day and 60-day SMAs further reinforces this short-term upward momentum. The relatively small change in the last market data suggests a stable recent trading day.

**3. Indicators Analysis**

*   **MRI:** 0.8 (Medium Investment Recommended)
*   **RSI:** 76.41 (Overbought)
*   **PPO:** 0.27
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (4 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-12-01)
*   **Recent Relative Divergence Change:** 1.7 (+) (Short-term increase)
*   **Expected Return:** -46.4%

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI indicates the stock is currently overbought and may be due for a correction.
*   The Hybrid Signal recommends full investment, indicating a positive outlook despite the overbought RSI.
*   The positive change in relative divergence suggests recent outperformance.
*   The expected return is negative, suggesting that, based on the model, long-term investments may underperform compared to current levels.

**4. Recent News & Significant Events**

*   **Acquisition of Foresight Diagnostics:** Natera closed the Foresight deal for $275M upfront and $175M earnouts.
*   **Insider Selling:** Solomon Moshkevich sold 3,000 shares.
*   **Valuation Assessment:** Articles discuss the valuation after a strong rally.
*   **Impact on Adaptive Biotechnologies:**  The Foresight acquisition is affecting Adaptive Biotechnologies' stock.
*   **ASH Signatera Lymphoma Data:**  Data is fueling growth optimism in hematology.

**Analysis:** The news is mixed. The acquisition is positive, signaling growth and expansion. However, insider selling can sometimes be interpreted negatively. Articles assessing valuation suggest awareness of the stock's recent surge. The data from ASH appears to be a positive catalyst.

**4-2) Analyst Opinions**

*   **Consensus:** Strong Buy (Mean: 1.47)
*   **Opinions:** 19 analysts
*   **Target Price:** Average: 237.05, High: 280.00, Low: 186.00

**Analysis:**  The analyst consensus is strongly positive, with a "Strong Buy" rating. However, the average target price is slightly below the current price, suggesting limited immediate upside, but the high target price shows some analysts see significant potential.

**5. Recent Earnings Analysis**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-11-07 | -0.64 | 0.59 B$      |
| 2025-08-08 | -0.74 | 0.55 B$      |
| 2025-05-09 | -0.50 | 0.50 B$      |
| 2024-11-12 | -0.26 | 0.44 B$      |
| 2025-11-07 | -0.26 | 0.44 B$      |

**Analysis:** Natera is not yet profitable, as indicated by the negative EPS. However, revenue is consistently growing quarter-over-quarter, which is a positive sign.

**6. Financial Information**

**Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $0.59B  | 64.91%        |
| 2025-06-30   | $0.55B  | 63.41%        |
| 2025-03-31   | $0.50B  | 63.12%        |
| 2024-12-31   | $0.48B  | 62.94%        |
| 2024-09-30   | $0.44B  | 61.79%        |

**Capital and Profitability:**

| Quarter      | Equity  | ROE      |
|--------------|---------|----------|
| 2025-09-30   | $1.25B  | -6.99%   |
| 2025-06-30   | $1.25B  | -8.10%   |
| 2025-03-31   | $1.24B  | -5.40%   |
| 2024-12-31   | $1.20B  | -4.50%   |
| 2024-09-30   | $0.88B  | -3.60%   |

**Analysis:** Revenue is growing, and profit margins are consistently high. Equity is also generally increasing. However, the Return on Equity (ROE) is negative, reflecting the company's current lack of profitability despite the high profit margin per revenue.

**7. Comprehensive Analysis (Summary)**

Natera (NTRA) has significantly outperformed the S&P 500, demonstrating strong growth potential in the genetic testing market. Recent news highlights strategic acquisitions and positive data releases, which are driving investor optimism. Analyst opinions are strongly favorable, but the RSI indicates the stock is overbought. Financials show strong revenue growth and high profit margins, although the company is not yet profitable, and ROE is negative. While the short-term outlook appears positive based on momentum and recent developments, the negative expected return suggests caution for long-term investments at current levels. Investors should carefully weigh the company's growth prospects against its current valuation and profitability challenges.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.